Stereotaxis (NYSE: STXS) reported mixed second-quarter results, with the robotic surgery company cutting guidance for the rest of the year.
The surgical robotics company, which specializes in minimally invasive endovascular interventions, reported yesterday evening a net loss of $4.5 million, or 5¢ per share, on revenue of $7.7 million for the three months ended June 30, 2026.
The net loss of 5¢ per share met the Wall Street consensus, but revenue missed the $8.35 million average estimate.
STXS shares were down more than 5% to $1.38 apiece by midday trading today. The S&P 500 was up slightly.
“Stereotaxis has reached an important commercial inflection point. Following years of product development and regulatory milestones, the company’s expanded robotic platform is now generating accelerating commercial adoption across multiple product lines,” David Fischel, Stereotaxis chair and CEO, said in a press release. “We are now witnessing the initial green shoots of commercial success, including quarterly revenue from our novel robotic catheters exceeding one million dollars, the first Synchrony system sales, and the first U.S. purchase of a GenesisX robot.”
“We are making methodical progress on the operational and commercial efforts needed to drive revenue growth. We expect continued momentum throughout this year as we ramp manufacturing and address commercial friction. We have line of sight to sustained revenue growth and reaching cash flow profitability in the coming quarters.”
Stereotaxis said it anticipates recurring revenue to grow approximately $7 million in the third quarter and $8 million in the fourth quarter of this year, driven by increases in MAGiC catheter manufacturing. The company expects system revenue to be approximately $3 million in each quarter, putting the expected totals at $10 million and $11 million, respectively, compared to the Q1 expectations of revenue exceeding $10 million. The company dropped the $40-million-plus annual revenue target it set in its first quarter results.
